bjective To evaluate the long-term efficacy of cinacalcet in hemodialysis patients with different levels of intact parathyroid hormone (iPTH) and secondary hyperparathyroidism (SHPT), so as to provide the information for clinical treatment of hemodialysis patients with SHPT. Methods A total of 47 SHPT patients treated during May 2010 to August 2019 online by Dr. Zhang Ling on “Well-known Doctor Online” as well as in the Hemodialysis Center, Department of Nephrology, Beijing Chuiyangliu Hospital were retrospectively analyzed. According to the baseline iPTH value, they were divided into two groups: <800pg/ml (group A) and ≥800pg/ml (group B). After cinacalcet therapy for 12 months, differences in serum calcium, phosphorus and iPTH were analyzed between the two groups. A decrease of iPTH ≥50% was defined as significant effective, and a decrease of iPTH≥30% was defined as effective. Results There were no differences in baseline indicators except iPTH level and the number of enlarged parathyroid glands by ultrasound examination between the two groups. Along with the cinacalcet treatment time, the compliance rate of serum calcium was higher in group A than in group B at the 6th month of the treatment (χ2=3.632, P=0.029) and had no difference between the two groups at the 12th month of the treatment (χ2=1.362, P=0.243); the compliance rate of serum phosphorus increased gradually, but had no statistical difference between the two groups at the 6th month and 12th month of the treatment (χ2=5.158 and 6.000, respectively; P=0.076 and 0.050, respectively); the mean iPTH value decreased significantly in both groups at the 6th month and 12th month of the treatment (Z=-2.728 and -1.852, respectively; P=0.003, 0.032), and there were no statistical differences in significant effective rate and effective rate between the two groups at the 6th month and 12th month of the treatment (χ2=0.011, 0.084, 0.869 and 0.254, respectively; P=0.917, 0.772, 0.351 and 0.614, respectively). The rate of iPTH decreased to ≤250pg/ml was higher in group A than in group B at the 6th month of the treatment (χ2=5.887, P=0.015) but had no difference between the two groups at the 12th month of the treatment (χ2=0.510, P=0.475). Conclusion Cinacalcet was effective in hemodialysis patients with different iPTH levels. The patients with iPTH <800pg/ml were more likely to reach the compliance level. Those with iPTH≥800pg/ml could also reach the compliance level with the extension of treatment course, suggesting that long-term use of cinacalcet can be beneficial even if parathyroid surgery was not available
FAN Xiao-Yan
,
ZHANG Ling
,
YU Yong-Wu
,
YANG Liu
. Long-term efficacy of cinacalcet in maintenance hemodialysis patients with different iPTH levels [J]. Chinese Journal of Blood Purification, 2022
, 21(05)
: 336
-340
.
DOI: 10.3969/j.issn.1671-4091.2022.05.008
[1] Komaba H，Taniguchi M，Wada A，et al.Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism［J］.Kidney Int，2015，88(2)：350-359.</br>[2] Khan S. Secondary hyperparathyroidism is associated with higher cost of care among chronic kidney disease patients with cardiovascular comorbidities.Nephron Clin Pract. 2007;105(4):c159-64. doi: 10.1159/000099006. Epub 2007 Jan 25. PMID: 17259740.</br>[3] Byrnes CA, Shepler BM. Cinacalcet: a new treatment for secondary hyperparathyroidism in patients receiving hemodialysis. Pharmacotherapy.2005，25(5):709-16. doi: 10.1592/phco.25.5.709.63595. PMID: 15899733.</br>[4] Block GA, Kilpatrick RD, Lowe KA, Wang W, Danese MD. CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis. Clin J Am Soc Nephrol. 2013 Dec;8(12):2132-40. doi: 10.2215/CJN.04260413. Epub 2013 Sep 19. PMID: 24052218; PMCID: PMC3848404.</br>[5] 国家肾脏疾病临床医学研究中心.中国慢性肾脏病矿物质和骨异常诊治指南概要[J].肾脏病与透析肾移植杂志,2019,28(1):52-57.</br>[6] 王海峰,张凌,姚力,等.三种不同甲状旁腺切除术治疗继发性甲状旁腺功能亢进425例疗效比较[J].中国血液净化,2016,15(9):455-458.</br>[7] Zhan Z, Smyth B, Toussaint ND, Gray NA,et al. Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study. BMC Nephrol. 2019 Jul 12;20(1):258-267. doi: 10.1186/s12882-019-1438-3. PMID: 31299919; PMCID: PMC6624904.</br>[8] Louie KS, Erhard C, Wheeler DC, Stenvinkel P, Fouqueray B, Floege J. Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes.J Nephrol. 2020 Aug;33(4):803-816. doi: 10.1007/s40620-019-00686-z. Epub 2019 Dec 17. PMID: 31848883; PMCID: PMC7381480.</br>[9] Block G A, Martin K J, de Francisco A L, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.[J].N Engl J Med, 2004, 350(15):1516-1525.</br>[10] Fukagawa M, Yumita S. Cinacalcet (KRN1493) effectively decreases the serum intact iPTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant. 2008; 23:328–335.</br>[11] Kawata T, Imanishi Y, Kobayashi K, et al. Direct in vitro evidence of the suppressive effect of cinacalcetHCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels[J].J Bone Miner Metab, 2006, 24(4):300-306.</br>[12] Changlin Mei, Nan Chen, Xiaoqiang Ding, et al.Efficacy and safety of Cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis.Hemodialysis international. International Symposium on Home Hemodialysis 2016 10;20(4):589-600</br>[13] Isakova T, Wolf MS. FGF23 or iPTH: which comes first in CKD ? Kidney Int. 2010 Nov;78(10):947-9. doi: 10.1038/ki.2010.281. PMID: 21030968.</br>[14] Liu CT, Hsu SC, Hsieh HL, Chen CH, Chen CY, Sue YM, Lin FY, Shih CM, Shiu YT, Huang PH. Parathyroid hormone induces transition of myofibroblasts in arteriovenous fistula and increases maturation failure.Endocrinology. 2021 Feb 26:bqab044. doi: 10.1210/endocr/bqab044. Epub ahead of print. PMID: 33640969.</br>[15] Rottembourg J, Ure?a-Torres P, Toledano D, et al. Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with cinacalcet in real-world clinical practice: Mimosa study. Clin Kidney J. 2019 Mar 18;12(6):871-879. doi: 10.1093/ckj/sfz021. PMID: 31807302; PMCID: PMC6885690.</br>[16] Block GA Chertow GM, Cooper K, et al. Fibroblast growth factor 23 as a risk factor for cardiovascular events and mortality in patients in the EVOLVE trial. Hemodial Int. 2021 Jan;25(1):78-85. doi: 10.1111/hdi.12887. Epub 2020 Oct 5. PMID: 33016505.</br>[17] Moe SM, Chertow GM, Parfrey PS, et al. Cinacalcet, fibroblast growth Factor-23, and cardiovascular disease in hemodialysis: The evaluation of Cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Circulation. 2015;132:27-39.</br>[18] Akizawa T, Kurita N, Mizobuchi M, et al. PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Sci Rep. 2016 Apr 13;6:19612. doi: 10.1038/srep19612. PMID: 27071541; PMCID: PMC4829837.
